Alkermes Plc · NASDAQ:ALKS
Alkermes — 36th Annual J.P. Morgan Healthcare Conference (January 2018)
5 slides from Alkermes's conference presentation, Jan 9, 2018
Slide 1: Great Science, Deep Compassion, Real Impact
Great Science Deep Compassion Real Impact JANUARY 9, 2018 Richard Pops Chief Executive Officer 36th Annual J.P. Morgan Healthcare Conference © 2018 Alkermes. All rights reserved. Alkermes* Patient inspired*
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
2 Forward-Looking Statements and Non-GAAP Financial Information Certain statements in this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning future financia
Slide 3: VIVITROL: Expanding Accessibility, Awareness and Use
VIVITROL®: Expanding Accessibility, Awareness and Use 13 Accessibility: Developing state and local ecosystems that encompass access and reimbursement, policy and treatment providers Awareness: Educating healthcare providers, public health officials, policymakers and employers: Implementation of CARA
Slide 4: ARISTADA: Gaining Traction in the Long-Acting Atypical Antipsychotic Market
Expanding differentiating features and data to drive broad uptake ALNCD initiation product PDUFA date of June 30, 2018 Study comparing ARISTADA and INVEGA SUSTENNA® initiated Q4 2017 Expanding commercial presence in hospital setting in 2018 Collaborating with policymakers and industry peers to impro
Slide 5: Strong Organization Built for Scale
Growing business with significant revenues and operational leverage Revenue growth driven by proprietary commercial products Base business with potential to grow to >$2B into 2020s Next phase of growth identified with late-stage pipeline assets Strong balance sheet with >$560M cash & investments (as
Alkermes — 36th Annual J.P. Morgan Healthcare Conference (January 2018) on 6ix